EUVIMEDEUVIMED entdecken
Übersichtsarbeit

T‐cell exhaustion in CAR‐T ‐cell therapy and strategies to overcome it

Xuechen Yin iD, Lingfeng He, Zhigang Guo

Immunology · 2023-08 · 169 (4) · 400-411

DOI: 10.1111/imm.13642 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 20.03.2023. Verfasst von Xuechen Yin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour immunotherapy has achieved good therapeutic effects in clinical practice and has received increased attention. Cytotoxic T cells undoubtedly play an important role in tumour immunotherapy. As a revolutionary tumour immunotherapy approach, chimeric antigen receptor T‐cell (CAR‐T‐cell) therapy has made breakthroughs in the treatment of haematological cancers. However, T cells are easily exhausted in vivo, especially after they enter solid tumours. The exhaustion of T cells can lead to poor results of CAR‐T‐cell therapy in the treatment of solid tumours. Here, we review the reasons for T‐cell exhaustion and how T‐cell exhaustion develops. We also review and discuss ways to improve CAR‐T‐cell therapy effects by regulating T‐cell exhaustion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansT-Cell ExhaustionImmunotherapy, AdoptiveCell- and Tissue-Based TherapyReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR-T-cell therapyT-cell exhaustionimmunotherapy

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.
  • CAR-T R&D, Nanjing Blue Shield Biotechnology Co., Ltd., Nanjing, 210023, China.

ORCID-Profile: Xuechen Yin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yin, X., He, L., & Guo, Z. (2023). T‐cell exhaustion in CAR‐T ‐cell therapy and strategies to overcome it. Immunology, 169(4), 400-411. https://doi.org/10.1111/imm.13642

Vancouver

Yin X, He L, Guo Z. T‐cell exhaustion in CAR‐T ‐cell therapy and strategies to overcome it. Immunology. 2023;169(4):400-411. doi:10.1111/imm.13642

BibTeX
@article{Yin2023,
  author = {Yin, Xuechen and He, Lingfeng and Guo, Zhigang},
  title = {T‐cell exhaustion in CAR‐T ‐cell therapy and strategies to overcome it},
  journal = {Immunology},
  year = {2023},
  volume = {169},
  number = {4},
  pages = {400--411},
  doi = {10.1111/imm.13642}
}
Kostenlos starten →